loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex]
loteprednol etabonate
RxCUI: 213262
What the CMS Formulary Data Shows for loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex]
Per the CMS 2026 Part D formulary file, loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] (RxNorm concept RXCUI 213262, generic name loteprednol etabonate) appears on 1 distinct formulary file spanning 10 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 3, with a cross-plan average of Tier 3.
Real-world access to loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 91,483 Part D beneficiaries filled loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] in 2023, with total plan-and-beneficiary spending of $33,190,775 and an average per-beneficiary annual cost of $362.81. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 10
- Coverage rate
- 0.2%
- Tier range
- Tier 3, Preferred Brand
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 91,483
- Total spending
- $33,190,775
- Avg per beneficiary
- $362.81
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex]
10 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Health First Rewards H1099-014 (HMO) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First SunSaver H1099-016 (HMO) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First Complete Care H1099-023 (HMO) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First Emerald Plus H1099-024 (HMO) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First Premier Access H1099-025 (HMO-POS) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First Emerald Plus H1099-026 (HMO) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First Premier Access H1099-027 (HMO-POS) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First Emerald Plus H1099-028 (HMO) | HEALTH FIRST HEALTH PLANS | T3 | No | $0 | FL |
| Health First Value H1099-006 (HMO) | HEALTH FIRST HEALTH PLANS | T3 | No | $15.00 | FL |
| Health First Classic H1099-001 (HMO-POS) | HEALTH FIRST HEALTH PLANS | T3 | No | $49.40 | FL |
Frequently Asked Questions
Is loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] covered by Medicare Part D?
Yes, loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] is covered by 10 Medicare Part D plans (0.2% of all Part D formularies).
What tier is loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] on Medicare Part D plans?
loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] averages Tier 3 across Part D plans, ranging from Tier 3 to Tier 3.
Does loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] require prior authorization?
0% of Part D formularies require prior authorization for loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex]?
In 2023, total Medicare Part D spending on loteprednol etabonate 2 MG/ML Ophthalmic Suspension [Alrex] was $33,190,775, covering 91,483 beneficiaries. The average spend per beneficiary was $362.81.
Read our methodology - how this data is sourced, computed, and verified.